Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis-Reference-Cited by-同舟云学术

Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis

Published:2020-08-24 Issue:9 Volume:58 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Ziegler Katharina¹,Rath Anca²,Schoerner Christoph²,Meyer Renate²,Bertsch Thomas³,Erbguth Frank⁴,Bogdan Christian²⁵,Steinmann Jörg¹,Held Jürgen²

Affiliation:

1. Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Klinikum Nürnberg, Nuremberg, Germany

2. Mikrobiologisches Institut-Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

3. Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Paracelsus Medical University, Klinikum Nürnberg, Nuremberg, Germany

4. Clinic of Neurology, Paracelsus Medical University, Klinikum Nürnberg, Nuremberg, Germany

5. Medical Immunology Campus Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Abstract

Diagnosis of Lyme neuroborreliosis (LNB) is challenging, as long as Borrelia -specific intrathecal antibodies are not yet detectable. The chemokine CXCL13 is elevated in the cerebrospinal fluid (CSF) of LNB patients. Here, we compared the performances of the Euroimmun CXCL13 enzyme-linked immunosorbent assay (CXCL13 ELISA) and the ReaScan CXCL13 lateral flow immunoassay (CXCL13 LFA), a rapid point-of-care test, to support the diagnosis of LNB. In a dual-center case-control study, CSF samples from 90 patients (34 with definite LNB, 10 with possible LNB, and 46 with other central nervous system [CNS] diseases [non-LNB group]) were analyzed with the CXCL13 ELISA and the CXCL13 LFA.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00207-20

Reference32 articles.

1. Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection

2. Rauer S Kastenbauer S. 2018. Neuroborreliose S3 Leitlinie. Deutsche Gesellschaft für Neurologie Leitlinien für Diagnostik und Therapie in der Neurologie. https://www.dgn.org/leitlinien. Accessed 19 June 2019.

3. Aguero-Rosenfeld M, Stanek G. 2019. Borrelia, p 1066–1078. In Caroll KC, Pfaller MA, Landry ML, McAdam AJ, Patel R, Richter SS, Warnock DW (ed), Manual of clinical microbiology, 12th ed, vol 1. ASM Press, Washington, DC.

4. Borrelia garinii Induces CXCL13 Production in Human Monocytes through Toll-Like Receptor 2

5. Editorial Commentary: Toward a Better Understanding of European Lyme Neuroborreliosis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CXCL13 as a biomarker in the diagnostics of European lyme Neuroborreliosis - A prospective multicentre study in Austria;Journal of Central Nervous System Disease;2024-05-02

2. Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges;Journal of Clinical Medicine;2023-06-26

3. Cerebrospinal fluid levels of the macrophage-specific biomarker sCD163 are diagnostic for Lyme neuroborreliosis: An observational cohort study;Clinica Chimica Acta;2023-03

4. CXCL13 in laboratory diagnosis of Lyme neuroborreliosis—the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samples;European Journal of Clinical Microbiology & Infectious Diseases;2021-10-09

5. The Usefulness of Two CXCL13 Assays on Cerebrospinal Fluid for the Diagnosis of Lyme Neuroborreliosis: a Retrospective Study in a Routine Clinical Setting;Journal of Clinical Microbiology;2021-08-18